Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Dec 21;6:1301. doi: 10.1038/s42003-023-05674-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a Workflow to discover anti-PGCC compounds. Day 0: cell loading; Day 1: induction of PGCCs by 1 μM Docetaxel treatment; Day 3: removal of supernatant and screening of a library of 172 compounds; Day 5: staining and imaging cells for single-cell morphological analysis. The diagram was generated with elements from the Biorender. b Representative images of SUM159 treated with DMSO control, 1 μM Docetaxel, Carfilzomib, and ML162. Cells were stained with Live (green), Dead (red), and Hoechst (blue) staining reagents. PGCCs are marked with red arrows. (Scale bar: 100 μm). c Screening the effects of 172 compounds using Vari068, MDA-MB-231, SUM149, and SUM159 breast cancer cells. The x-axis represents the number of PGCCs after treatment, and the y-axis represents the number of non-PGCCs. Each dot represents the treatment of a compound. Different colors are used to indicate different classes of compounds. Statistical analysis is provided in Supplementary Data 4, 5. d Treatments of selected compounds (Docetaxel, ML162, Carfilzomib, and Actinomycin D) at 5 concentrations (10 μM, 1 μM, 0.1 μM, 0,01 μM, and 0.001 μM) on SUM159 cells. The x-axis represents the concentration of the selected compound. The left y-axis (black) represents the number of non-PGCCs, and the right y-axis (red) represents the number of PGCCs. The black curve indicates the number of non-PGCCs, and the red curve indicates the number of PGCCs. Error bars indicate the standard error of the mean (SEM), n = 3. e Dynamics of cell status. SUM159 cells pre-treated with Docetaxel for 2 days to induce PGCCs were treated with Docetaxel, ML162, Carfilzomib, and Actinomycin D and imaged every 30 min for 3 days. The x-axis represents time (hours), the left y-axis (black) represents the number of non-PGCCs, and the right y-axis (red) represents the number of PGCCs. The black curve indicates the number of non-PGCCs, and the red curve indicates the number of PGCCs. (n = 4).